India’s post-pandemic pharma pivot takes centre stage in this issue of Business Today. The June 8 cover story dives into the transformation of Serum Institute of India (SII)—once the world's leading Covid vaccine supplier, now innovating its way forward.
The June 8 cover feature offers an in-depth analysis of the strategic transformation underway at Serum Institute of India (SII). Once the world’s foremost supplier of Covid-19 vaccines, SII, under the leadership of Adar Poonawalla, is recalibrating its operational focus toward a future anchored in research-intensive vaccine innovation, global market penetration, and diversified sectoral investments.
As pandemic-driven revenues normalize, SII is charting a renewed trajectory through the development of India’s first indigenous HPV vaccine and ambitions to secure regulatory approvals in the US and EU markets. Parallelly, the group’s pivot into non-core verticals spans diagnostics, financial services via Poonawalla Fincorp, and an unexpected equity stake in film production giant Dharma Productions, underscoring a bold diversification strategy.
Also in focus are the broader industry landscape amid the waning relevance of pandemic-era high performers and a sharp editorial reflection on Pakistan’s economic freefall and its militarised roots.
This issue encapsulates the dual themes of corporate reinvention and geopolitical reckoning—two sides of a global post-crisis reset.
All this and more in the latest issue of BT Magazine. Out on stands now!
SUBSCRIBE NOW
by Siddharth Zarabi
by Krishna Gopalan
Market Buzz
